Clearmind Medicine receives patent publication for obesity therapy

Clearmind Medicine Inc. (NASDAQ: CMND) announced the publication of an international patent application for a combination therapy targeting obesity and metabolic syndrome. The patent application was published under the European Patent Office as part of the company's collaboration with SciSparc Ltd. (NASDAQ: SPRC).

The patent covers a combination therapy using Clearmind's 5-methoxy-2-aminoindane (MEAI) and SciSparc's Palmitoylethanolamide (PEA) for treating metabolic syndrome and obesity. According to the company, metabolic syndrome affects up to one-third of U.S. adults and includes conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels.

The Clearmind-SciSparc collaboration has resulted in the filing of 13 patent families across multiple jurisdictions, including the United States, Europe, and China. The partnership focuses on developing therapies that combine neuroplastogen molecules with N-acylethanolamines to address mental health disorders, addictions, and metabolic conditions.

"We continue our strategy to develop breakthrough therapies to treat complex health conditions, with our intellectual property portfolio enabling us to potentially redefine therapeutic approaches for metabolic syndrome and obesity," stated Dr. Adi Zuloff-Shani, CEO of Clearmind.

Clearmind is a clinical-stage biotech company focused on psychedelic-derived therapeutics. The company's intellectual property portfolio includes 19 patent families with 31 granted patents. Clearmind shares trade on NASDAQ under the symbol CMND and on the Frankfurt Stock Exchange under CWY0.

You May Also Be Interested In

• GLJ Research Downgrades Fluence Energy Inc. (FLNC) to Hold
• SuperCom wins third Texas electronic monitoring contract
• Wingspire Equipment Finance closes $140M AI compute infrastructure deal